Economic burden of moderate to severe plaque psoriasis in Canada

Levy, Adrian R.; Davie, Alison M.; Brazier, Nicole C.; Jivraj, Farah; Albrecht, Lorne; Gratton, David; Lynde, Charles

doi:10.1111/j.1365-4632.2011.05359.x

Cited by 52 publications

(50 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the COI analyses conducted by Fonia et al (UK) 353 [28] and Driessen et al (the Netherlands) [29] all patients 354 were treated with biological drugs. The biological treat-355 ment rate was 16 % in the study by Ghatnekar et al 356 (Sweden) [34], 13 % by Levy and colleagues (Canada) 357 [33], 6 % by Steinke et al (Germany) [36] [32]. Only one study by Gleason and 359 colleagues (US) did not report the rate of biological therapy 360 [31].…”

mentioning

confidence: 87%

“…361 Studies that provided costs specifically for BST groups 362 or subgroups were selected for comparison. Neither the 363 study by Gleason et al (US) [31] nor the one by Levy et al 364 (Canada) [33] reported costs data for BST group, therefore, 365 these were excluded. Moreover, only eight patients 366 received biological agent in the study by Steinke et al [36] Journal : Large [34] and Le Moigne (France, 2013) [32] 371 (Table 4).…”

mentioning

confidence: 99%

“…347 Therefore, we performed a literature search for COI studies 348 for the period from January 2010 to December 2013 using 349 the same search terms and databases as Raho et al [9].Our 350 search identified a further nine publications [28][29][30][31][32][33][34][35][36], seven 351 of which involved psoriasis patients with biological treat-352 ment. In the COI analyses conducted by Fonia et al (UK) 353 [28] and Driessen et al (the Netherlands) [29] all patients 354 were treated with biological drugs.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

et al. 2014

View full text Add to dashboard Cite

10 Background Despite the widespread availability of bio-11 logical drugs in psoriasis, there is a shortage of disease 12 burden studies. 13 Objectives To assess the cost-of-illness and quality of 14 life of patients with moderate to severe psoriasis in 15 Hungary. 16 Methods Consecutive patients with Psoriasis Area and 17 Severity Index (PASI) [ 10 and Dermatology Life Quality 18 Index (DLQI) [ 10, or treated with traditional systemic 19 (TST) or biological systemic treatment (BST) were inclu-20 ded. Demographic data, clinical characteristics, psoriasis 21 related medication, health care utilizations and employ-22 ment status in the previous 12 months were recorded. 23 Costing was performed from the societal perspective 24 applying the human capital approach. Quality of life was 25 assessed using DLQI and EQ-5D measures. 26 Results Two-hundred patients were involved (females 27 32 %) with a mean age of 51 (SD 13) years, 103 (52 %) 28 patients were on BST. Mean PASI, DLQI and EQ-5D 29 scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), 30 respectively. The mean total cost was €9,254/patient/year 31 (SD 8,502) with direct costs accounting for 86 %. The 32 main cost driver was BST (mean €7,339/patient/year).

show abstract

mentioning

confidence: 87%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

et al. 2014

View full text Add to dashboard Cite

show abstract

“…A recent review considered only seven studies dealing with the costs of psoriasis [5]. Psoriasis is is thought to be one of the most costly dermatological diseases due to its high prevalence [6]. Estimates of per-patient costs vary considerably depending on disease severity [7, 8].…”

Section: Introductionmentioning

confidence: 99%

Treatment costs of psoriasis in a tertiary-level clinic

Mustonen

Leino

Mattila

et al. 2014

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundThe costs of psoriasis to a tertiary-level clinic vary considerably depending on the country of study and methods used. Hospitalisation and phototherapy have been significant cost components. This study was performed to estimate the distribution and relative magnitude of the costs of psoriasis to a tertiary-level clinic.MethodsBased on 233 patients, outpatient and phototherapy visits and the days hospitalised were collected from the treatment provider’s records. The visit costs represented true costs, used to charge the final payers. Patients were analysed according to their treatment modalities.ResultsOn average, hospitalised patients (3.4%) had 31-fold higher total costs than non-hospitalised patients (p < 0.0001). The costs of hospitalisations formed 45% of all the treatment costs to the entire study population. Phototherapy accumulated 19% of the overall treatment costs. Patients receiving biological drugs or both phototherapy and traditional systemic therapy had the highest costs of treatment.ConclusionsThe current study indicates that a small percentage of all psoriasis patients generate a large proportion of the overall costs to a tertiary-level hospital. Treatment modality has a significant effect on the costs to a tertiary-level hospital.Electronic supplementary materialThe online version of this article (doi:10.1186/1472-6963-14-344) contains supplementary material, which is available to authorized users.

show abstract

“…Productivity loss due to psoriasis has been estimated to 2-26 days/patient per year, depending on the setting, severity and methods used (6,(24)(25)(26)(27). Treatment with biologics has resulted in decreased absence from work in psoriasis patients (28)(29)(30), but the findings are often limited to clinical trials.…”

mentioning

confidence: 99%

Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden

Norlin¹,

Carlsson²,

Persson³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

The introduction of biologics has changed treatment patterns as well as costs in patients with psoriasis. This study was performed to estimate direct and indirect costs of the psoriasis population in Sweden, and to analyse changes in costs between 2006 and 2009. The study population was identified in national registers. Direct costs included health care visits with primary psoriasis diagnoses in specialist care and drugs relevant for treating psoriasis. Productivity loss, including costs of long-term sick leave and disability pension, was estimated as the difference between psoriasis patients and matched controls from the general population. Total direct cost increased from SEK 348 million (~ €39) in 2006 to SEK 459 million (~ €51) in 2009, whereas the total productivity loss decreased from SEK 1,646 (~ €183) to 1,618 million (~ €180) between 2006 and 2009. Although direct costs, especially for biologic agents, have increased for patients with psoriasis over time, this study indicates that costs related to productivity loss are still more substantial.

show abstract

Economic burden of moderate to severe plaque psoriasis in Canada

Cited by 52 publications

References 30 publications

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

Treatment costs of psoriasis in a tertiary-level clinic

Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden

Contact Info

Product

Resources

About